Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
In This Article:
Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.